Concord Biotech DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.75×0.76×0.75×0.75×
1.14×1.17×1.10×1.08×
28.2%27.8%37.7%37.2%
0.49×0.49×0.64×0.60×
1.12×1.11×1.12×1.11×
13.1%13.4%22.2%20.3%
13.6%13.6%22.3%21.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CONCORDBIO₹1,230.60

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹12,874 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×—0.750.750.760.75
Interest Burden (Pretax/EBIT) ×—1.081.101.171.14
EBIT Margin %—37.1737.6627.7728.15
Asset Turnover ×—0.600.640.490.49
Financial Leverage (Assets/Equity) ×—1.111.121.111.12
ROE (5-step product, year-end total equity) %—20.2522.2413.3513.14
ROE (owners' profit / average owners' equity) %—21.8822.2613.6313.63
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.